2014
Su1050 Statin Use Is Associated With Sustained Virological Response in Patients With Hepatitis C Treated With Pegylated Interferon and Ribavirin, Independent of Host Metabolic Factors
Sanchez M, Augustin S, Balakrishnan M, Re V, Tate J, Garcia-Tsao G. Su1050 Statin Use Is Associated With Sustained Virological Response in Patients With Hepatitis C Treated With Pegylated Interferon and Ribavirin, Independent of Host Metabolic Factors. Gastroenterology 2014, 146: s-974-s-975. DOI: 10.1016/s0016-5085(14)63541-1.Peer-Reviewed Original ResearchO64 EFFECT OF BASELINE NS5A POLYMORPHISMS ON VIROLOGIC RESPONSE TO THE ALL-ORAL COMBINATION OF DACLATASVIR + SOFOSBUVIR ± RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION
McPhee F, Zhou N, Yang X, Hernandez D, Chiarella J, Kozal M. O64 EFFECT OF BASELINE NS5A POLYMORPHISMS ON VIROLOGIC RESPONSE TO THE ALL-ORAL COMBINATION OF DACLATASVIR + SOFOSBUVIR ± RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION. Journal Of Hepatology 2014, 60: s26-s27. DOI: 10.1016/s0168-8278(14)60066-0.Peer-Reviewed Original Research
1990
A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy
Roberts R, Hollinger F, Parks W, Rasheed S, Laurence J, Heseltine P, Makuch R, Lubina J, Johnson K, Group R. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy. AIDS 1990, 4: 67-72. PMID: 1690551, DOI: 10.1097/00002030-199001000-00009.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAIDS-Related ComplexDouble-Blind MethodFemaleGene Products, gagHIVHIV AntigensHIV Core Protein p24HIV InfectionsHumansMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesRNA-Directed DNA PolymeraseUnited StatesViral Core ProteinsConceptsOral ribavirinPeripheral blood mononuclear cellsPlacebo-controlled trialBlood mononuclear cellsMulticenter clinical trialHIV isolationP24 antigenemiaStudy drugMulticenter trialActive treatmentDaily dosesMononuclear cellsClinical trialsMedical CenterWeek 6HIV activityAdult menRibavirinTrialsLymphadenopathyHIVInterlaboratory variationCritical roleAntigenemiaPlaceboA multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group.
Roberts R, Dickinson G, Heseltine P, Leedom J, Mansell P, Rodriguez S, Johnson K, Lubina J, Makuch R. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 884-92. PMID: 1974628.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdministration, OralAdolescentAdultCD4 AntigensCD4-Positive T-LymphocytesDose-Response Relationship, DrugDouble-Blind MethodEvaluation Studies as TopicHumansImmunoblastic LymphadenopathyLeukocyte CountMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesConceptsOral ribavirinActive treatmentBaseline CD4 cell countMajor protocol violationsCD4 cell countPlacebo-controlled trialMulticenter clinical trialSignificant differencesPlacebo patientsPlacebo groupPlacebo treatmentStudy entryTreat analysisWashout periodDaily dosesClinical trialsKaposi's sarcomaProtocol violationsMedical CenterTreatment superiorityTreatment groupsPlaceboRibavirinPatientsOverall significant difference
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply